New Report Available: Mexico Pharmaceuticals & Healthcare Report Q3 2016

The government's efforts to improve competitiveness in Mexico's pharmaceutical sector combined with the countr y's economic outperformance compared with lar ge countries like Brazil will improve Mexico's attractiveness t o drugmakers.

Headline Expenditure Projections

Pharmaceuticals: MXN177.3bn (USD11.2bn) in 2015 to MXN182.7bn (USD10.3bn) in 2016; +3.0% in local currency terms and -7.6% in US dollar terms.

Healthcare: MXN1,131.8bn (USD71.3bn) in 2015 to MXN1,193.5bn (USD67.4bn) in 2016; +5.5% in local currency terms and -5.4% in US dollar terms.

Risk/Reward Index

Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the sixth-most attractive pharmaceutical market in the Americas. Its score is unchanged from our assessment for the previous quarter, although it falls one place in the ranking on account of an improved assessment of Chile. Both reward and risk components are above the regional average, indicating Mexico is a market with strong potential for returns and a relatively stable political and regulatory environment.

Full Report Details at
- http://www.fastmr.com/prod/1197530_mexico_pharmaceuticals.aspx?afid=301

Latest Updates

In May 2016, Amgen announced the development of nine biosimilars in Mexico and the intention to launch the first biosimilar drug for breast cancer treatment in 2018 for the local market.

In March 2016, Biocon, through its wholly-owned subsidiary, Biocon SA, entered into an agreement with Mexico-based Laboratorios PiSA for the co-development and commercialisation of a generic recombinant human insulin (rh-insulin) product for the US market. The agreement with Lab PiSA is an extension of a long-standing relationship of over ten years between the two firms. Biocon's insulin glargine was approved in Mexico in 2015 through the country's new bio-comparable approvals pathway. Biocon will be responsible for clinical development, regulatory approvals and commercialisation of the product in the US. Mexico remains on the Watch List in the industry body's 2016 Special 301 submission. Particular concerns were intellectual property issues and formulary access.

BMI Economic View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Qatar Pharmaceuticals & Healthcare Report Q3 2016
- Turkey Pharmaceuticals & Healthcare Report Q3 2016
- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- United Arab Emirates Pharmaceuticals & Healthcare Report Q3 2016